+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Immunotherapy Market - Global Forecast 2026-2032- Product Image
Cancer Immunotherapy Market - Global Forecast 2026-2032- Product Image
Sale

Cancer Immunotherapy Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010622
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Immunotherapy Market is projected to reach USD 157.81 Billion in 2026. It is expected to continue growing at a CAGR of 7.52%, reaching USD 244.72 Billion by 2032.

Cancer immunotherapy has moved from a specialized oncology approach to a core pillar of cancer treatment, reshaping standards of care across hematologic malignancies and solid tumors. Immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, antibody-drug conjugate combinations, therapeutic cancer vaccines, oncolytic viruses, cytokine-based therapies, and tumor-infiltrating lymphocyte therapies are now central to clinical and commercial strategies.

The growth imperative is supported by verified epidemiology. The International Agency for Research on Cancer reported approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022 and projects more than 35 million new cancer cases by 2050. This rising burden is accelerating demand for durable, biomarker-guided, and combination-based immuno-oncology treatments that can improve survival while supporting precision medicine adoption.

Transformative Shifts in the Immunotherapy Landscape

The cancer immunotherapy landscape is being transformed by a shift from single-agent therapies toward rational combinations, earlier-line treatment, and biomarker-selected patient populations. PD-1, PD-L1, and CTLA-4 inhibitors established immuno-oncology as a mainstream treatment category, while next-generation modalities are addressing resistance, relapse, and tumor microenvironment suppression.

Manufacturing and delivery models are also changing. Autologous cell therapy capacity, allogeneic platforms, decentralized manufacturing, vein-to-vein logistics, and real-world evidence programs are becoming competitive differentiators. At the same time, payers and health technology assessment agencies are applying stricter scrutiny to durability, quality-adjusted survival, safety management, and total cost of care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across cancer immunotherapy discovery, development, and commercialization. AI-enabled target discovery, antigen prediction, neoantigen prioritization, spatial biology analysis, digital pathology, and multimodal biomarker modeling are helping researchers identify patients most likely to respond and design more precise treatment strategies.

In clinical operations, AI supports trial matching, eligibility screening, site selection, adverse event signal detection, and real-world evidence generation. The most immediate value is not replacing clinical judgment but improving decision speed, reducing failed enrollment, and strengthening companion diagnostic strategies. Leaders that combine AI governance, high-quality datasets, and regulatory-grade validation are positioned to accelerate immuno-oncology innovation responsibly.

Key Regional Insights

North America remains a global center for cancer immunotherapy innovation due to dense clinical trial networks, advanced academic cancer centers, FDA regulatory pathways, and strong biopharma financing. The United States anchors early adoption of checkpoint inhibitors, cell therapies, bispecific antibodies, and biomarker testing, while Canada contributes through public health systems, oncology research networks, and precision medicine initiatives supported by evidence-based reimbursement review.

Europe is shaped by EMA oversight, national reimbursement systems, and health technology assessment requirements that prioritize evidence quality, cost-effectiveness, and real-world outcomes. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia increase clinical research output, biologics manufacturing, regulatory modernization, and oncology infrastructure. Latin America, led by Brazil and Mexico, is improving specialty access and clinical trial participation but continues to face affordability, pathology, and molecular diagnostic capacity constraints. The Middle East, particularly GCC markets, is investing in tertiary cancer centers, genomic medicine, and specialty procurement, while Africa’s opportunity depends on strengthening pathology, cold-chain logistics, oncology workforce capacity, pharmacovigilance, and equitable access programs.

Key Group Insights

The G7 continues to drive premium immuno-oncology innovation through mature regulatory systems, high clinical trial density, specialized cancer centers, and established reimbursement pathways, making it a critical launch environment for checkpoint inhibitors, cell therapies, bispecific antibodies, and companion diagnostics. NATO markets overlap with many advanced oncology systems and also highlight the importance of secure pharmaceutical supply chains, data protection, cyber-resilient clinical infrastructure, and resilient biologics manufacturing.

The European Union benefits from centralized EMA authorization and a growing emphasis on joint health technology assessment, which can improve market consistency while maintaining pressure on comparative effectiveness and value demonstration. BRICS countries offer population scale, expanding clinical research participation, increasing domestic biologics capacity, and rising demand for oncology access, though availability varies significantly by reimbursement, diagnostics, and infrastructure. ASEAN markets are advancing unevenly, with Singapore, Thailand, and Malaysia showing stronger specialty oncology capabilities, while broader regional adoption depends on workforce development, pathology access, and affordability. GCC countries are using national transformation agendas to expand precision oncology, specialty procurement, genomic medicine, and regional cancer care hubs.

Key Country Insights

The United States leads cancer immunotherapy commercialization through FDA approvals, advanced biomarker testing, broad clinical trial access, academic cancer networks, and strong life sciences financing. Canada emphasizes evidence-based adoption through provincial reimbursement systems and pan-Canadian oncology assessment processes. Mexico and Brazil represent important Latin American access markets, with progress tied to public-private oncology capacity, specialty distribution, clinical research participation, and diagnostic expansion.

In Europe, the United Kingdom combines NHS real-world evidence capabilities with strong oncology research, while Germany and France are central to reimbursement evaluation, clinical adoption, and biomarker testing infrastructure. Italy and Spain contribute robust oncology networks and expanding access to precision medicine, while Russia maintains domestic oncology demand despite geopolitical, regulatory, and supply access complexity. In Asia-Pacific, China has become a major immuno-oncology development engine supported by large clinical trial activity and domestic biologics capacity; India offers large patient populations, expanding biosimilar capabilities, and rising oncology infrastructure; Japan supports high-quality regulatory and clinical infrastructure with strong adoption of innovative oncology therapies; South Korea is strong in biologics, digital health, and cell therapy innovation; and Australia remains a preferred clinical trial destination with globally respected cancer centers and strong translational research capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development, combination strategies with clear mechanistic rationale, and trial designs that demonstrate durable benefit in defined patient segments. Strong companion diagnostic planning, inclusive enrollment, decentralized trial capabilities, and real-world evidence generation are essential to improve clinical utility, regulatory confidence, and payer acceptance.

Manufacturers should strengthen cell and gene therapy supply chains, invest in scalable manufacturing, and build capabilities for adverse event management, including cytokine release syndrome and immune-related toxicities. Commercial teams should prepare access dossiers that address survival, quality of life, durability, site-of-care economics, and long-term value. Partnerships with academic centers, diagnostic developers, AI platforms, contract manufacturers, and regional health systems can accelerate access, operational resilience, and differentiation.

Research Methodology

The executive summary is developed using a secondary research approach grounded in publicly available and authoritative sources, including cancer epidemiology from international health agencies, regulatory information from major agencies, clinical trial registries, peer-reviewed oncology literature, health technology assessment practices, oncology guideline updates, and immuno-oncology development activity.

The methodology emphasizes triangulation across epidemiological data, therapeutic approvals, clinical development patterns, regional healthcare infrastructure, reimbursement dynamics, manufacturing considerations, diagnostics adoption, and technology signals. Insights are synthesized to support strategic decision-making for executives, investors, manufacturers, diagnostics developers, healthcare providers, and policy stakeholders operating across the cancer immunotherapy value chain.

Conclusion

Cancer immunotherapy is entering a more complex and value-driven phase defined by precision biomarkers, advanced biologics, engineered cell therapies, AI-enabled discovery, and regional access differentiation. The sector’s long-term opportunity is supported by rising global cancer incidence and continued clinical progress across both hematologic malignancies and solid tumors.

Sustainable leadership will depend on evidence generation, scalable manufacturing, equitable access, diagnostic readiness, and disciplined access strategies. Organizations that align innovation with measurable patient outcomes, safety management, real-world value, and payer expectations will be best positioned to compete in the evolving global cancer immunotherapy landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Immunotherapy Market, by Therapy Type
7.1. Introduction
7.2. Cancer Vaccines
7.3. CAR-T Therapy
7.4. CTLA-4 Inhibitors
7.5. Oncolytic Virus Therapy
7.6. PD-1 Inhibitors
7.7. PD-L1 Inhibitors
8. Cancer Immunotherapy Market, by Mechanism Of Action
8.1. Introduction
8.2. Adoptive Cell Transfer
8.3. Checkpoint Inhibitors
8.4. Cytokine Therapy
8.5. Oncolytic Virus Therapy
8.6. Vaccine Therapy
9. Cancer Immunotherapy Market, by Line Of Therapy
9.1. Introduction
9.2. First Line
9.3. Fourth Line And Beyond
9.4. Second Line
9.5. Third Line
10. Cancer Immunotherapy Market, by Route Of Administration
10.1. Introduction
10.2. Intratumoral
10.3. Intravenous
10.4. Subcutaneous
11. Cancer Immunotherapy Market, by Indication
11.1. Introduction
11.2. Hematologic Malignancies
11.2.1. Leukemia
11.2.2. Lymphoma
11.2.3. Multiple Myeloma
11.3. Solid Tumors
11.3.1. Breast Cancer
11.3.2. Colorectal Cancer
11.3.3. Lung Cancer
11.3.4. Melanoma
12. Cancer Immunotherapy Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Research Institutes
12.4. Specialty Clinics
13. Cancer Immunotherapy Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Cancer Immunotherapy Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Cancer Immunotherapy Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Canada
15.9. Italy
15.10. Australia
15.11. South Korea
15.12. Brazil
15.13. Mexico
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Adaptimmune Therapeutics
17.2. Amgen Inc.
17.3. Astellas Pharma Inc.
17.4. AstraZeneca PLC
17.5. Bayer AG
17.6. BeiGene, Ltd.
17.7. BioNTech SE
17.8. Boehringer Ingelheim
17.9. Bristol-Myers Squibb Company
17.10. Cellectis S.A.
17.11. Daiichi Sankyo Company, Limited
17.12. Eli Lilly and Company
17.13. Fate Therapeutics, Inc.
17.14. Gilead Sciences, Inc.
17.15. GlaxoSmithKline plc
17.16. Immunocore Holdings PLC
17.17. Iovance Biotherapeutics, Inc.
17.18. Johnson & Johnson
17.19. Merck & Co.
17.20. Moderna, Inc.
17.21. Novartis AG
17.22. Pfizer Inc.
17.23. Regeneron Pharmaceuticals, Inc.
17.24. Roche Holding AG
17.25. Sanofi
17.26. Takeda Pharmaceutical Company
List of Figures
FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CAR-T THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CAR-T THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CAR-T THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ADOPTIVE CELL TRANSFER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ADOPTIVE CELL TRANSFER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ADOPTIVE CELL TRANSFER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL VACCINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL VACCINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL VACCINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL FOURTH LINE AND BEYOND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL FOURTH LINE AND BEYOND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL FOURTH LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INTRATUMORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INTRATUMORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INTRATUMORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 111. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 112. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 113. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 114. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 115. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 116. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 117. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 138. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 139. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 140. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 142. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 143. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 144. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 157. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 158. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 159. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 160. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 161. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 162. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 163. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 164. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 166. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 167. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 168. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 169. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 170. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 171. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 172. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 184. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 185. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 186. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 188. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 189. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 190. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 193. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 194. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 195. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 197. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 198. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 199. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 202. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 203. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 204. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 205. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 206. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 207. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 208. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 209. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 220. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 221. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 222. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 223. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 224. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 225. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 226. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 227. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 229. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 230. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 231. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 232. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 233. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 234. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 235. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 236. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 237. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 239. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 240. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 241. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 243. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 244. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 245. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 248. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 249. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 250. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 252. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 253. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 254. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 266. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 267. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 268. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 269. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 270. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 271. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 272. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 274. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 275. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 276. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 277. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 279. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 280. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 281. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 284. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 285. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 286. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 288. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 289. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 290. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 302. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 303. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 304. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 305. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 306. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 307. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 308. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 320. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 321. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 322. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 323. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 324. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 325. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 326. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 327. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 328. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 329. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 330. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 331. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 332. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 333. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 334. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 335. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 336. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 338. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 339. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 340. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 341. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 342. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2017-2032 (USD MILLION)
TABLE 343. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 344. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 345. GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
TABLE 346. GLOBAL CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Adaptimmune Therapeutics
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • BioNTech SE
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cellectis S.A.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immunocore Holdings PLC
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Merck & Co.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Takeda Pharmaceutical Company

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 157.81 Billion
Forecasted Market Value ( USD ) by 2032 $ 244.72 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Cellular Immunotherapy - Global Strategic Business Report - Product Image

Cellular Immunotherapy - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Cancer Immunotherapy - Global Strategic Business Report - Product Image

Cancer Immunotherapy - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
America Cancer Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

America Cancer Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 130 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.